Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 6/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15691793 | 1.00 | NCF1 (0.37) | NCF1GBA1SLC6A3 | |
| SCHEMBL22183582 | 0.84 | NCF1 (0.38) | NCF1GBA1 | |
| SCHEMBL10044406 | 0.83 | NCF1 (0.37) | NCF1GBA1 | |
| SCHEMBL10044405 | 0.83 | NCF1 (0.37) | NCF1GBA1 | |
| SCHEMBL6628057 | 0.83 | NCF1 (0.37) | NCF1GBA1 | |
| SCHEMBL24789560 | 0.83 | NCF1 (0.37) | NCF1GBA1 | |
| SCHEMBL12536103 | 0.83 | NCF1 (0.37) | NCF1GBA1 | |
| SCHEMBL12536133 | 0.82 | NCF1 (0.39) | NCF1GBA1 | |
| SCHEMBL12536056 | 0.82 | NCF1 (0.39) | NCF1GBA1 | |
| SCHEMBL19087104 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| US-8361962-B2 | Tricyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | BILLEDEAU ROLAND JOSEPH | 2011-01-27 | — | — | US | disclosed |
| US-7338965-B2 | 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | PHARMACIA & UPJOHN COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | NCF1 1421/4885GBA1 3872/4885SLC6A3 3846/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | NCF1 1785/4885GBA1 2320/4885SLC6A3 4137/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | NCF1 1421/4885GBA1 3872/4885SLC6A3 3846/4885 |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | JAK3, JAK1, JAK2 | NCF1 410/4885GBA1 2452/4885SLC6A3 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.